Therapeutic value of cisplatin-based neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer
10.3781/j.issn.1000-7431.2013.09.013
- Author:
En-Ling LIU
1
Author Information
1. Department of Obstetrics and Gynecology
- Publication Type:Journal Article
- Keywords:
Cisplatin;
Docetaxel;
Epithelial ovarian carcinoma;
Neoadjuvant chemotherapy;
Ovarian neoplasms
- From:
Tumor
2013;33(9):827-830
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To explore the efficacy and safety of NAC (neoadjuvant chemotherapy) with docetaxel and cisplatin in patients with advanced epithelial ovarian cancer. Methods: Ninety-eight hospitalized patients with advanced ovarian cancer admitted to our hospital between January 2005 and July 2012 were randomly individed into NAC group (n = 48, receiving 2 cycles of NAC with docetaxel and cisplatin followed by cytoreductive surgery and 6 cycles of adjuvant chemotherapy with docetaxel and cisplatin) and the control group (n = 50, receiving cytoreductive surgery and 6-8 cycles of adjuvant chemotherapy with docetaxel and cisplatin). The mean blood loss, duration of operation and the rate of optimal cytoreductive surgery betweem the two groups were observed and compared. The side effects of chemotherapy and the survival were analyzed. Results: The amount of blood loss and the duration of operation of the NAC group were less than those of the control group (P < 0.05). The rate of optimal cytoreductive surgery of the NAC group was higher than that of the control group (85.4% vs 48.0%, P < 0.001). The median survival time and the median progression-free survival time were both longer than those of the control group (39 vs 31 months, P < 0.05; 27 vs 20 months, P < 0.05). The side effects of chemotherapy were not significantly different between the two groups. Conclusion: The NAC regimen with docetaxel and cisplatin can enhance the rate of optimal cytoreductive surgery, reduce the amount of blood loss, shorten the duration of operation, and improve the overall survival of patients with advanced epithelial ovarian cancer. Copyright © 2013 by TUMOR.
